Cancer and other related diseases have done so much havoc on many lives that most people find it difficult imagining a world free of these ailments. These folks should not be castigated for this, they and their loved ones may have seen and passed through horrible times in battle this monster called cancer, but there are now some reasons to be positive. Time and space will not permit me to dive into all the reasons. However, I will try and do some justice to one – the unrelenting effort of Dr Mikhail Blagosklonny against cancer and aging.
Mikhail Blagosklonny has always had one goal, rescuing men and women including the young and old from the shackles of cancer and aging. He submitted himself to training by fulfilling all necessary requirements for the award of an MD in Internal Medicine at the prestigious First Pavlov State Medical University of St. Petersburg. He was not done with just an MD. He studied further and earned a PhD in a PhD from the same University. Visit classroomvoices.org to read more about Mikhail.
He wanted working experience in some of the most equipped organizations in the world in terms of human know-how and up-to-date technologically advanced medical facilities. This took him to work in places such as New York Medical College as an associate professor, Ordway Research Institute as a senior scientist, and Roswell Park Cancer Institute as a professor of Oncology to date.
If cancer could speak like humans, it will single out Mikhail Blagosklonny as one of the fiercest enemies. He has carried out hundreds of researches all in the bid to discover more effective targeted cancer therapies. This dynamic man came up with a hypothesis called TOR signaling which has proven very helpful in combating cancer and aging. The world will always remember him for this. He is also a strong advocate of rapamycin as an effective drug for cancer since it helps to retard the growth of tumors and by extension the aging process.
With the likes of Mikhail Blagosklonny, the devastation done by cancer and aging on humans will soon be a thing of the past, so it is not out of place to start thinking of a cancer-free world. Read more on templeofthecave.com
Seattle Genetics has been continuing its projects with the largest funding possible. The company has increased its $480 million public stock offering to $552 million. They did this because of the over-allotment option.
Seattle Genetics has been able to increase the stock amounts because of the large amounts of interest offered from investors. In addition to using the funds for drug pipeline and expanding the use of its flagship cancer drug Adcetris, Seattle Genetics will continue to bring in more employees and expand their work environment. The company is planning on hiring at least one hundred new employees every year over the course of the next five years. That would mean the company would have to make room for over 1200 employees by 2020.
Seattle Genetics is looking at other buildings to lease near Canyon Park area of Bothell. The company is located at 21823 30th Dr. S.E. The company is working on pushing growth as fast as possible. There have been no promises yet, but there are expected to be more buildings under their name in the new future.
Seattle Genetics was founded in 1998. The have now grown to be one of the largest biotech companies. However, they are not at the stage where they can earn much profit. The company has made a good amount of profit from selling Adcetris, but all the medical equipment and research costed the company a lot of money. CEO of the company, Siegall, has said that the lack of profit thus far has nothing to do with future growth. There is still so much to build.
It is common for biotech companies to to take a long time before earning any significant profit. Seattle Genetics is continuing their research to find all possible uses for Adcetris beyond cancer. They will continue to advance drugs through their pipeline.
Clay Siegall is the president of Seattle Genetics. He earned his Bachelor of Science in Zoology at the University of Maryland and a Doctor of Philosophy. He helped grow the company until it became an industry leader. Siegall has multiple licenses with affiliated companies such as ADC technology, including with Genentech (Roche), AbbVie, GlaxoSmithKline and Pfizer. He has earned $675 million through public and private funding.